Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Intellia Therapeutics

Rank#5346

Market Cap1.65B

CountryUnited States

Summary

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

History

Intellia was founded in 2014 by world-renowned scientists, including four of the inventors of CRISPR/Cas9. The company's mission is to enable precise and efficient therapeutic somatic gene editing to create curative medicines for serious diseases, initially focusing on liver diseases.

Mission

Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Vision

Intellia Therapeutics' vision is to become a fully integrated gene-editing biopharmaceutical company, advancing the healthcare of tomorrow by unlocking the full potential of CRISPR/Cas9.

References

https://en.wikipedia.org/wiki/Intellia_Therapeutics

https://in.investing.com/equities/intellia-therapeutics-inc

https://finance.yahoo.com/quote/NTLA/profile?p=NTLA

https://www.comparably.com/companies/intellia-therapeutics/mission

https://www.crunchbase.com/organization/intellia-therapeutics

https://sec.report/CIK/0001652130

https://companiesmarketcap.com/

https://www.intelliatx.com

Leadership team

Dr. John M. Leonard M.D. (Pres, CEO & Director)

Mr. Glenn G. Goddard CPA (Exec. VP, CFO & Treasurer)

Dr. Laura Sepp-Lorenzino Ph.D. (Exec. VP & Chief Scientific Officer)

Products / Services

Biotechnology, Genetics, Health Care, Medical, Therapeutics

Number of Employees

100 - 500

Address

Cambridge, Massachusetts, United States

Established

2014-01-01

Company Registration

SEC CIK number: 0001652130

Revenue

20M - 100M

Traded as

NTLA

Website

https://www.intelliatx.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Intellia Therapeutics

Rank#5346

Market Cap1.65B

CountryUnited States

Summary

History

Mission

Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Vision

Intellia Therapeutics' vision is to become a fully integrated gene-editing biopharmaceutical company, advancing the healthcare of tomorrow by unlocking the full potential of CRISPR/Cas9.

References

https://en.wikipedia.org/wiki/Intellia_Therapeutics

https://in.investing.com/equities/intellia-therapeutics-inc

https://finance.yahoo.com/quote/NTLA/profile?p=NTLA

https://www.comparably.com/companies/intellia-therapeutics/mission

https://www.crunchbase.com/organization/intellia-therapeutics

https://sec.report/CIK/0001652130

https://companiesmarketcap.com/

https://www.intelliatx.com

Leadership team

Dr. John M. Leonard M.D. (Pres, CEO & Director)

Mr. Glenn G. Goddard CPA (Exec. VP, CFO & Treasurer)